Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027
Source
32 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027
–Quarterly Revenue of $195.3 million –
Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million —
Full Page Monetization Live Across All NBCUniversal; Fox News Live 100%;
Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year
FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026
Record Third Quarter Revenue of $361 Million, Up 20% YoY
Q3 revenue increased 40% year-over-year to a record $252 million, driven by robust marketplace growth.